Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | BX-912 | 3 | 72 | 0.0032 | 3155.3 | 3280.0 | 586.9 | -2.49 | 0.969 | 0.962 | 2.483 | BT20 BX912 0 3 |
| BT-20 | BX-912 | 3 | 72 | 0.01 | 3417.5 | 3280.0 | 586.9 | -2.0 | 1.030 | 1.040 | 2.483 | BT20 BX912 0 3 |
| BT-20 | BX-912 | 3 | 72 | 0.032 | 3484.8 | 3280.0 | 586.9 | -1.49 | 1.050 | 1.060 | 2.483 | BT20 BX912 0 3 |
| BT-20 | BX-912 | 3 | 72 | 0.1 | 3086.3 | 3280.0 | 586.9 | -1.0 | 0.952 | 0.941 | 2.483 | BT20 BX912 0 3 |
| BT-20 | BX-912 | 3 | 72 | 0.32 | 3097.3 | 3280.0 | 586.9 | -0.495 | 0.954 | 0.944 | 2.483 | BT20 BX912 0 3 |
| BT-20 | BX-912 | 3 | 72 | 1.0 | 3049.3 | 3280.0 | 586.9 | 0.0 | 0.942 | 0.930 | 2.483 | BT20 BX912 0 3 |
| BT-20 | BX-912 | 3 | 72 | 3.2 | 2600.3 | 3280.0 | 586.9 | 0.505 | 0.821 | 0.793 | 2.483 | BT20 BX912 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 0.001 | 2642.5 | 3415.3 | 586.9 | -3.0 | 0.808 | 0.774 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 0.0032 | 3274.5 | 3415.3 | 586.9 | -2.49 | 0.967 | 0.959 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 0.01 | 3139.5 | 3415.3 | 586.9 | -2.0 | 0.935 | 0.919 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 0.032 | 2758.3 | 3415.3 | 586.9 | -1.49 | 0.839 | 0.808 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 0.1 | 3078.5 | 3415.3 | 586.9 | -1.0 | 0.920 | 0.901 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 0.32 | 2797.8 | 3415.3 | 586.9 | -0.495 | 0.849 | 0.819 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 1.0 | 1703.0 | 3415.3 | 586.9 | 0.0 | 0.521 | 0.499 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | Alpelisib | 3 | 72 | 3.2 | 930.3 | 3415.3 | 586.9 | 0.505 | 0.199 | 0.272 | 2.541 | BT20 BYL719 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 0.001 | 3235.5 | 3531.5 | 586.9 | -3.0 | 0.934 | 0.916 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 0.0032 | 3273.5 | 3531.5 | 586.9 | -2.49 | 0.942 | 0.927 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 0.01 | 3281.5 | 3531.5 | 586.9 | -2.0 | 0.944 | 0.929 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 0.032 | 3378.3 | 3531.5 | 586.9 | -1.49 | 0.966 | 0.957 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 0.1 | 3386.0 | 3531.5 | 586.9 | -1.0 | 0.968 | 0.959 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 0.32 | 3346.8 | 3531.5 | 586.9 | -0.495 | 0.959 | 0.948 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 1.0 | 3187.5 | 3531.5 | 586.9 | 0.0 | 0.922 | 0.903 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 3.2 | 3158.8 | 3531.5 | 586.9 | 0.505 | 0.916 | 0.894 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.001 | 1827.0 | 3144.8 | 586.9 | -3.0 | 0.598 | 0.581 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.0032 | 1762.8 | 3144.8 | 586.9 | -2.49 | 0.575 | 0.561 | 2.422 | BT20 Everolimus 0 3 |